Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06511401 · ClinicalTrials.gov registry record · NA
Informing Pain Treatment Using Pharmacogenomic Analysis
A NA study of Adult Patients Who Are Receiving Oncologic Care, sponsored by University of Chicago.
- Recruiting
- Registry status
- NA
- Development phase
- 800
- Enrollment target
- 1
- Study location
NCT06511401: Recruiting NA study of Adult Patients Who Are Receiving Oncologic Care, sponsored by University of Chicago.
NCT06511401 is a NA study of Adult Patients Who Are Receiving Oncologic Care that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 800 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06511401, a NA study of Adult Patients Who Are Receiving Oncologic Care, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- NA
- Development phase
- 800 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, prospective study to evaluate the effects of preemptive pharmacogenomic (PGx) testing on opioid dosing decisions/selections and pain score in cancer patients.
Primary Outcome
Measuring changes in composite pain intensity rating via the numeric rating scale: * Brief Pain Inventory-Short Form (BPI-SF) * Score range: 0 (no pain) to 10 (most pain) * Composite pain intensity score (mean of worst, least, average, and current pain) From baseline to day 45 in patients receiving an index opioid prescription for codeine, tramadol, or hydrocodone.
Conditions Studied
Interventions
- OTHER Pharmacogenomic (PGx) results.
Study Locations (1)
Illinois
- University of Chicago Medicine Comprehensive Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2024-07-30 |
| Est. Completion | 2028-03-31 |
| Phase | NA |
What NCT06511401 shows while recruiting
NCT06511401 is an interventional study that assigns participants to a tested intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (43% lower).
The record links to 1 condition, with Adult Patients Who Are Receiving Oncologic Care appearing as the primary indexed condition, and to 1 intervention - of which Pharmacogenomic (PGx) results. is the first listed.
NCT06511401 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06511401 about?
NCT06511401 is a clinical study titled "Informing Pain Treatment Using Pharmacogenomic Analysis". This is a randomized, prospective study to evaluate the effects of preemptive pharmacogenomic (PGx) testing on opioid dosing decisions/selections and pain score in cancer patients.
What is the current status of trial NCT06511401?
This trial is currently recruiting. It is a NA study. The enrollment target is 800 participants. The study started on 2024-07-30. Estimated completion is 2028-03-31.
What conditions does trial NCT06511401 study?
This clinical trial studies the following conditions: Adult Patients Who Are Receiving Oncologic Care.
What interventions are being tested in trial NCT06511401?
The interventions under investigation include: Pharmacogenomic (PGx) results. (OTHER).
Who is sponsoring clinical trial NCT06511401?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06511401 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06511401's enrollment target sits among peer trials
800 135th of 2000 higher than 1,861 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI